- Home
- VNRX
VNRX
VolitionRX Limited
as 06-20-2025 4:00pm EST
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HENDERSON |
| Market Cap: | 52.4M | IPO Year: | N/A |
| Target Price: | $3.88 | AVG Volume (30 days): | 307.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $0.94 | Next Earning Date: | 08-13-2025 |
| Revenue: | $1,308,361 | Revenue Growth: | 64.16% |
| Revenue Growth (this year): | 563.72% | Revenue Growth (next year): | 160.43% |
Stock Insider Trading Activity of VolitionRX Limited (VNRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Reynolds Cameron John | VNRX | President and CEO | Jun 12 '25 | Buy | $0.59 | 12,500 | $7,372.50 | 2,331,722 | |
| Innes Guy Archibald | VNRX | Director | Jun 3 '25 | Buy | $0.54 | 20,000 | $10,772.00 | 888,689 | |
| Micallef Jacob Vincent | VNRX | Chief Scientific Officer | May 19 '25 | Buy | $0.43 | 50,000 | $21,500.00 | 426,033 | |
| Reynolds Cameron John | VNRX | President and CEO | May 19 '25 | Buy | $0.44 | 20,000 | $8,730.00 | 2,331,722 | |
| Innes Guy Archibald | VNRX | Director | Mar 26 '25 | Buy | $0.55 | 181,818 | $99,999.90 | 888,689 | |
| Reynolds Cameron John | VNRX | President and CEO | Mar 26 '25 | Buy | $0.55 | 181,818 | $99,999.90 | 2,331,722 |
Latest VolitionRX Limited News
VNRX Breaking Stock News: Dive into VNRX Ticker-Specific Updates for Smart Investing
PR Newswire
9 days ago
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
PR Newswire
16 days ago
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
Zacks Small Cap Research
25 days ago
VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applications, particularly cancer & sepsis.
PR Newswire
a month ago
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
GuruFocus.com
a month ago
VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones
Associated Press Finance
a month ago
VolitionRX: Q1 Earnings Snapshot
PR Newswire
a month ago
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
GuruFocus.com
a month ago
VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For
Compare VNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNRX VolitionRX Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.